GSK Reports the EMA’s MAA Acceptance of Bepirovirsen to Treat Chronic Hepatitis B

Why It Matters

Bepirovirsen offers a potential first‑in‑class cure‑oriented approach that could reduce lifelong antiviral use and reshape the chronic hepatitis B market.

Key Takeaways

• EMA accepts marketing authorization for bepirovirsen.
• Phase III trials show higher cure rates vs standard care.
• Benefit greatest in patients with baseline HBsAg ≤3000 IU/ml.
• Trials spanned 29 countries, enhancing global data robustness.
• Results to be presented at conference, published 2026.

Pulse Analysis

Chronic hepatitis B remains a global health challenge, affecting an estimated 300 million people and driving significant morbidity, mortality, and healthcare costs. Current standard‑of‑care relies on nucleos(t)ide analogues that suppress viral replication but rarely achieve functional cure, leaving patients on indefinite therapy. The unmet need for treatments that can clear hepatitis B surface antigen (HBsAg) and restore immune control has spurred intense research into novel modalities, including gene‑silencing approaches.

Bepirovirsen, GSK’s antisense oligonucleotide, targets viral mRNA to reduce HBsAg production, positioning it as a potential first‑in‑class functional cure therapy. In the Phase III B‑Well 1 and B‑Well 2 studies, patients receiving bepirovirsen alongside nucleos(t)ide analogues achieved markedly higher functional cure rates than those on standard therapy alone, with the greatest benefit observed in individuals whose baseline HBsAg was ≤3000 IU/ml. The trials, conducted across 29 countries, provide robust, geographically diverse data that strengthen the regulatory dossier and underscore the drug’s efficacy across varied patient populations.

The EMA’s acceptance of the marketing‑authorization application signals a pivotal regulatory milestone, accelerating the path toward market entry. If approved, bepirovirsen could disrupt the chronic hepatitis B market, offering a finite treatment course that reduces long‑term drug exposure and associated costs. Investors and clinicians alike will watch forthcoming conference presentations and the 2026 peer‑reviewed publication for deeper efficacy and safety insights, which will shape pricing strategies, reimbursement negotiations, and clinical adoption worldwide.